Investors

Shareholder Tools

 

Overview

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious diseases. The Company’s lead product candidate is HEPLISAV, an investigational adult hepatitis B vaccine. For more information visit www.dynavax.com

Recent Press Releases

Jun 11, 2013
Dynavax to Present at the William Blair 33rd Annual Growth Stock Conference

Jun 10, 2013
Dynavax Reports Feedback From FDA Meeting Regarding HEPLISAV(TM) Biologic License Application

View all releases »

E-Delivery of Stockholder Communications

Beneficial stockholders

Registered stockholders

Corporate Presentation

Annual Report and Proxy
2013 Proxy Statement
2012 Form 10-K